Skip to main content
OpenTrials

Clinical trial condition

Lymphoma

Explore clinical trials studying Lymphoma. Study availability and eligibility vary by location and protocol.

3,652 public trials 850 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma trial results

Completed

T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma

NCT01142674

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Stanford University Medical Center Palo Alto, California, United States
  • Yale Cancer Center New Haven, Connecticut, United States
  • St Louis Washington University St Louis, Missouri, United States
  • University of Nebraska Medical Center Omaha, Nebraska, United States
View all 76 locations
View Trial Details
Completed

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

NCT02401048

Conditions
Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Hemic and Lymphatic Diseases, +11 more
Locations
  • Site-0397 Birmingham, Alabama, United States
  • Site-0047 Duarte, California, United States
  • Site-0038 Stanford, California, United States
  • Site-0388 Miami, Florida, United States
View Trial Details
Completed

A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)

NCT02213263

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Pacific Cancer Medical Center, Inc. Anaheim, California, United States
  • The Oncology Institute of Hope and Innovation Anaheim, California, United States
  • Compassionate Care Research Group, Inc., at Compassionate Cancer Care Medical Group, Inc. Corona, California, United States
  • The Oncology Institute of Hope and Innovation Downey, California, United States
View all 423 locations
View Trial Details
Completed

To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL

NCT02624492

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Jessa Ziekenhuis - Campus Virga Jesse Hasselt, Belgium
  • Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy
  • Istituto Clinico Humanitas Rozzano (MI), Italy
  • A. O. S. Maria della Misericordia Udine, Italy
View Trial Details
Completed

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

NCT01008462

Conditions
B-Cell Prolymphocytic Leukemia, Blood Protein Disorders, Cardiovascular Diseases, +51 more
Locations
  • Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
  • Froedtert and the Medical College of Wisconsin Milwaukee, Wisconsin, United States
View Trial Details
Completed

A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)

NCT02187861

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Southern Cancer Center, PC Mobile, Alabama, United States
  • Arizona Cancer Center Tucson, Arizona, United States
  • UCLA School of Medicine; Hematology/Oncology Los Angeles, California, United States
  • Nothwest Georgia Oncology Centers P.C Austell, Georgia, United States
View all 71 locations
View Trial Details

Related conditions